SLNO saw increased activity in its latest session, recording 2.59 million shares traded, which surpassed its average volume of 2.03 million. The Biotechnology company, operating within the Healthcare sector, moved between an intraday high of $50.30 and a low of $45.79. Over the past 52 weeks, SLNO has traded between $41.50 at its lowest and $90.32 at its highest, showcasing notable volatility. Analysts currently assign the stock a 1-year price target of $113.54, while its beta of –3.05 signals an unusually inverse correlation to market movements.
Price Performance and Earnings Outlook
SLNO’s recent market performance reflects mixed momentum with a tilt toward decline. Over the past week, the stock posted a 2.53% gain, but this rebound has not offset deeper losses. The stock fell 26.28% over the past month, 26.46% over three months, and 34.31% over six months. Despite these drops, SLNO remains 10.72% higher over the past year, although it has declined 8.90% year-to-date.
The company’s trailing twelve-month EPS stands at –1.84, yet analysts project a significant turnaround with 4.06 expected next year and 0.61 forecast for the next quarter. These estimates point to an EPS growth rate of 104.23% for the current year and a dramatic 2088.79% increase anticipated next year, signaling high expectations for performance improvement.
Share Structure and Short Interest
SLNO currently has 53.70 million shares outstanding, with 49.25 million available as public float. Short interest remains elevated, with 9.73 million shares sold short as of November 14, 2025, a substantial increase from the earlier reporting period.
The company is led by Dr. Anish Bhatnagar, M.D., who serves as Chairman, President, CEO, and COO, alongside Mr. James H. MacKaness, the firm’s CFO and Compliance Officer.
Financial Performance: Recent Quarterly Highlights
In its fiscal quarter ending September 30, 2025, SLNO reported $66.02 million in revenue and $22.72 million in operating income. The company’s EBITDA reached $28.52 million, while diluted EPS came in at $0.47, reflecting solid quarterly profitability. These financial results underscore operational progress despite ongoing stock volatility.
Analyst Ratings and Price Target Forecast
SLNO is currently followed by three analysts, all of whom issue BUY ratings. None recommend SELL, HOLD, OVERWEIGHT, or UNDERWEIGHT positions, indicating strong confidence in the company’s long-term prospects.
Price targets show significant upside potential, with analysts projecting:
- High target: $145.00
- Low target: $75.00
- Average target: $113.53846
Based on these projections, SLNO could surge 191.34% if it reaches its high target, climb 50.69% to reach the low target, and gain 128.13% if it hits the average price estimate.
EPS: Estimates vs. Actual Performance
Analysts’ annual EPS estimates for SLNO fall within a negative range, from –$3.8168 on the high end to –$3.95274 on the low end, averaging –$3.89 for the year. The previous quarter showed an earnings surprise of –$0.46, reflecting weaker-than-expected results at that time.
For the upcoming quarter, projections range from $0.23 to $1.08, with an average forecast of $0.69, highlighting expectations for improved performance in the near term.
